The Impact of Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens in the Management of Advanced Esophago-gastric Cancer in Hong Kong
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 主要终点
- Composite preparation, dispensing, and administration time
研究概览
简要总结
The objective of this study is to compare the possible time savings from reduction of nursing and pharmacy time to manage AEGC patients using capecitabine-based regimens versus traditional intravenous chemotherapy in the Hong Kong public hospital setting.
详细描述
Advanced esophageal and gastric cancer (AEGC) have ranked in the top 10 cancer-related cause of death worldwide, with approximately one million new cases each year. Over half of new cases are in East Asia. The traditional chemotherapy for AEGC remains on intravenous (IV) fluorouracil (5-FU), cisplatin, and the anthracyclines. Trials favoured the combined use of 5-FU and cisplatin for superior efficacy and quality of life in AEGC patients. Recent years, oral chemotherapy has a more practical and economic advantages over IV regimen. It is understandable that patients prefer oral regimens as long as the clinical efficacy is maintained. Oral treatment strategy preserves quality of life for AEGC patients. In addition, it may also have additional cost saving in the nursing and pharmacy time. It is because a significant amount of time can be saved in both nursing and pharmacy for the preparation and administration of IV chemotherapy However, there is a lack of local data to demonstrate the impact of pharmacy and nursing care utilizing capecitabine-based regimen comparing to traditional IV chemotherapy in MCRC patients of Hong Kong.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 or above
- •Diagnosed with AEGC and were prescribed with either XELOX-based or FOLFOX4- based chemotherapy treatment
排除标准
- •Persons < 18 years of age;
- •Pregnant or lactating women;
- •Persons related unequally to investigators (e.g. student, employee);
- •Special population (e.g. prisoner, mentally, congnitively disabled);
- •Patients who refused to sign consent or not willing to participate.
结局指标
主要结局
Composite preparation, dispensing, and administration time
时间窗: Up to 6 months after initiation of chemotherapy
This is a time-and-motion study conducted in 2 public hospitals of Hong Kong based on the simulation of previously data on both capecitabine-based regimen (XELOX and XP) and IV 5-FU-based regimen (FOLFOX and FP)
次要结局
未报告次要终点
研究者
Vivian Wing Yan Lee
Associate Professor
Chinese University of Hong Kong